Overview

Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to assess the relationship (both crude and adjusted) between voriconazole utilization and the development of non-melanoma skin cancer among adult patients who received a lung or heart/lung transplant and were continuously enrolled in a large U.S. commercial health plan.

Details

Lead Sponsor:

Pfizer

Collaborator:

University of Southern California

Treatments:

Voriconazole